Antibiotics

Improving outcomes for patients through new and innovative antibiotics.


AstraZeneca is committed to discovering and developing compounds to improve patient care in antibiotics

AstraZeneca is one of few large pharmaceutical companies with a strong late-stage pipeline for antibiotics. We are focusing on the fast growing global health threat of multidrug resistant bacterial infections and continue to bring scientific innovation from our antibiotics portfolio to doctors and patients around the world. We are committed to collaborating with stakeholders and partnering with governments as we aim to ensure the availability of effective new treatments for patients with life-threatening infections.

The challenges we face

Antibiotics have been heralded as one of the greatest breakthroughs of modern medicine. But in recent years we have seen the rapid development of resistant bacteria. As a result we could be entering into a post-antibiotic era, where antibiotics no longer work and minor infections could kill. Read on to learn about some of the most problematic bacteria and explore the impact of antibiotic resistance on modern medicine.


An exciting pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Infection, Neuroscience and Gastrointestinal (as at 29 April 2016)

Phase 1

Phase 1

  • AZD8108 suicidal ideation
  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • ATM AVI targeted serious bacterial infections
  • AZD3241 multiple system atrophy
  • CXL MRSA
  • MEDI2070 Crohn’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3/Reg.*

Phase 3/Reg.*

  • AZD3293 AMARANTH DAYBREAK-ALZ Early Alzheimer's disease
  • Zavicefta (CAZ AVI) serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • Zavicefta (CAZ AVI) hospital-acquired pneumonia/ ventilator-associated pneumonia
  • Zinforo pneumonia/skin infections
  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)